34
Infection dynamics, disease burden and health economic considerations
35
Despite excellent public health systems, alveolar echinococcosis (AE), a zoonosis due to infection 36 with the larval form of the fox tapeworm E. multilocularis [1] , is expanding in Europe ( 
50
[9-12]. With a time delay of 10-15 years, such changes in definitive host ecology can lead to an 51 increase in the incidence of human AE cases as already documented in some areas [13] [14] [15] [16] [17] .
52
Across the total population of endemic countries such as France, Germany, Austria and
53
Switzerland, AE is considered as a rare disease with average incidences of 0.03 to 0.30/100,000 54 inhabitants/year. These numbers, however, do not reflect the situation of the actual population 55 at risk; far higher incidences, from 4.7 to 8.1 cases per 100,000 inhabitants/years are observed 56 in nested clusters of E. multilocularis infection in the same countries [15, 15] . Several studies 57 found a recent upward trend in incidence [13] [14] [15] [16] 
224
vaccine has already been applied in a preliminary explorative study in macaques [27] . Therefore,
225
an anti-AE-vaccine to be applied in humans at risk of infection may become realistic not only 226 from the scientific point of view, but also in terms of economic considerations. Examples of 227 other vaccines developed against rather rare but severe and geographically restricted diseases,
228
such as tick-borne encephalitis in endemic regions in Europe, support this approach [62] .
229
On the treatment side, immunotherapy, i.e. modulating the AE-patient's immune response,
230
could be an attractive treatment option. For this, tracing the efficient immune pathways of 231 infection-resistant persons, and those in immunosuppressed and susceptible patients is required.
232
Specifically selected candidate-immunomodulating agents such as those tackled by Bardonnet et
233
al.
[30] should be evaluated for their clinical application.
235

Concluding remarks
236
The currently observed trends of E. multilocularis infection in the European fox and dog
237
populations and the expected increase of annual case numbers of human AE in many areas of
238
Europe strongly advocate for scaling up research that can improve the fields necessary to yield 239 better management of this infectious health problem in Europe (Box 1):
240
• prevention has to be tackled at two specific levels: (a) decreasing or abrogating infection 
245
• as long as prevention, as outlined above, cannot be optimally implemented, society has to face 246 the fact that new clinical cases of AE will occur. Prognosis of AE can be considerably improved
247
when an early diagnosis and a respectively appropriate treatment option can be offered.
248
• alternatively, if people e.g. at high exposition risk could be vaccinated against AE, such an 249 approach might represent an attractive option especially for areas with high infection risk.
From the medical point of view, the focus on developing improved therapeutic tools and 251 strategies appears as a key requirement, as this is often the only option for handling AE cases. 
268
(ii) Improve the management of E. multilocularis infection in definitive hosts (wildlife and 269 domestic domain).
270
(iii) Promote earlier diagnosis through improved imaging, immunological and molecular tools.
271
(iv) Promote accurate treatment assessment and prognostically improved follow-up of AE 
